Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson's UK to advance potential disease-modifying treatment MTX325.

Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK to advance their potential disease-modifying treatment for Parkinson's disease, called MTX325. MTX325 is a small molecule inhibitor designed to protect dopamine-producing neurons by improving mitochondrial quality and function. The funding will support a 28-day dosing of MTX325 in patients with early-stage Parkinson's disease to assess its safety, tolerability, pharmacokinetic profile, and effects on disease biology biomarkers. This grant highlights the potential of MTX325 as a disease-modifying treatment and endorses Mission Therapeutics' mitophagy strategy in human diseases. [Extracted from the article]